Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDCoherus Oncology, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$0.35 | -$0.26 | -$0.30 |
| Q2 2025 | 3 | -$0.27 | -$0.14 | -$0.22 |
| Q3 2025 | 1 | -$0.42 | -$0.31 | -$0.35 |
| Q4 2025 | 1 | -$0.40 | -$0.30 | -$0.34 |
| Q1 2026 | 1 | -$0.32 | -$0.23 | -$0.27 |
| Q2 2026 | 1 | -$0.33 | -$0.24 | -$0.28 |
| Q3 2026 | 1 | -$0.26 | -$0.19 | -$0.22 |
| Q4 2026 | 1 | -$0.26 | -$0.19 | -$0.22 |
| Q1 2027 | 1 | -$0.20 | -$0.15 | -$0.17 |
| Q2 2027 | 1 | -$0.20 | -$0.15 | -$0.17 |
| Q3 2027 | 1 | -$0.22 | -$0.17 | -$0.19 |
| Q4 2027 | 1 | -$0.22 | -$0.17 | -$0.19 |
| Q1 2028 | 0 | $0.00 | $0.00 | $0.00 |
| Q2 2028 | 0 | $0.00 | $0.00 | $0.00 |
| Q3 2028 | 0 | $0.00 | $0.00 | $0.00 |
| Q4 2028 | 0 | $0.00 | $0.00 | $0.00 |
Coherus Oncology, Inc. Earnings Date And Information
Coherus Oncology, Inc. last posted its earnings results on Thursday, November 6th, 2025. The company reported $-0.33 earnings per share for the quarter, missing analysts' consensus estimates of $-0.32 by $0.01. The company had revenue of 11.57 M for the quarter and had revenue of 266.96 M for the year. Coherus Oncology, Inc. has generated $0 earnings per share over the last year ($0.25 diluted earnings per share) and currently has a price-to-earnings ratio of 0.96. Coherus Oncology, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 6th, 2025 based on prior year's report dates.
Coherus Oncology, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2025 | Q3 2025 | -$0.32 | -$0.31 | 0.01 | $13.36 M | $11.57 M |
| 08/07/2025 | Q2 2025 | -$0.31 | -$0.36 | -0.05 | $9.35 M | $10.25 M |
| 05/12/2025 | Q1 2025 | -$0.31 | -$0.49 | -0.18 | N/A | $7.60 M |
| 03/17/2025 | Q4 2024 | N/A | -$0.44 | N/A | N/A | $54.14 M |
| 11/06/2024 | Q3 2024 | -$0.10 | -$0.09 | 0.01 | $58.98 M | $70.77 M |
| 08/08/2024 | Q2 2024 | -$0.21 | -$0.11 | 0.1 | $62.06 M | $64.98 M |
| 05/09/2024 | Q1 2024 | -$0.05 | $0.91 | 0.96 | N/A | $2.31 M |
| 03/15/2024 | Q4 2023 | N/A | -$0.71 | N/A | N/A | $91.52 M |
| 11/06/2023 | Q3 2023 | -$0.21 | -$0.41 | -0.2 | $81.78 M | $74.57 M |
| 08/02/2023 | Q2 2023 | -$0.52 | -$0.49 | 0.03 | $50.47 M | $58.72 M |
| 05/08/2023 | Q1 2023 | -$0.61 | -$0.94 | -0.33 | $46.29 M | $32.44 M |
| 03/06/2023 | Q4 2022 | -$0.64 | -$0.85 | -0.21 | $47.69 M | $45.35 M |
| 11/08/2022 | Q3 2022 | -$0.53 | -$1.19 | -0.66 | $56.69 M | $45.42 M |
| 08/04/2022 | Q2 2022 | -$0.96 | -$0.73 | 0.23 | $62.04 M | $60.15 M |
| 05/05/2022 | Q1 2022 | -$0.80 | -$1.44 | -0.64 | $69.54 M | $60.12 M |
| 02/23/2022 | Q4 2021 | N/A | -$0.60 | N/A | $82.61 M | $73.37 M |
| 11/08/2021 | Q3 2021 | -$0.40 | -$0.49 | -0.09 | $90.69 M | $82.50 M |
| 08/05/2021 | Q2 2021 | -$0.25 | -$0.40 | -0.15 | $87.04 M | $87.64 M |
| 05/06/2021 | Q1 2021 | $0.09 | -$2.37 | -2.46 | $96.20 M | $83.03 M |
| 02/25/2021 | Q4 2020 | N/A | $0.13 | N/A | $114.89 M | $110.42 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Coherus Oncology, Inc. Earnings: FAQ's
Coherus Oncology, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 6th, 2025 based offlast year's report dates.
The conference call for Coherus Oncology, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Coherus Oncology, Inc.'s latest earnings report can be read online.
Coherus Oncology, Inc. (:CHRS) has a recorded annual revenue of $266.96 M.
Coherus Oncology, Inc. (:CHRS) has a recorded net income of $28.51 M.Coherus Oncology, Inc. has generated $0.25 earnings per share over the last four quarters.
Coherus Oncology, Inc. (:CHRS) has a price-to-earnings ratio of 0.96 and price/earnings-to-growth ratio is -0.06.